hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.
about
Opposite action of peroxisome proliferator-activated receptor-gamma in regulating renal inflammation: functional switch by its ligandNew molecular medicine-based scar management strategiesHepatocyte Growth Factor Prevented High-Fat Diet-Induced Obesity and Improved Insulin Resistance in Mice.ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expressionHepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus.Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells.Mouse hepatic oval cells require Met-dependent PI3K to impair TGF-β-induced oxidative stress and apoptosis.Neuroprotectin/protectin D1: endogenous biosynthesis and actions on diabetic macrophages in promoting wound healing and innervation impaired by diabetes.tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosisProgression of glomerular and tubular disease in pediatrics.The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects.The Role of PPARs in Lung Fibrosis.Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosisRegulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis.Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signalingPPARγ activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines.Rapid Identification of Potential Drugs for Diabetic Nephropathy Using Whole-Genome Expression Profiles of Glomeruli.A Novel Mechanism of PPARgamma Regulation of TGFbeta1: Implication in Cancer BiologyCardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertensionRosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gammaPPARs and the kidney in metabolic syndrome.Racial differences between blacks and whites with systemic sclerosisRenal interstitial cells, proteinuria and progression of lupus nephritis: new frontiers for old factors.Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator.Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis.TGF-beta signal transduction in chronic kidney diseaseMadecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-γ in colon.PPAR modulation of kinase-linked receptor signaling in physiology and disease.PPARγ and chronic kidney disease.PAI-1 in tissue fibrosis.Improvement of metabolic syndrome by irbesartan via the PPARγ/HGF pathway in apolipoprotein E knockout mice.Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts.Mesenchymal Stem/Stromal Cells in Liver Fibrosis: Recent Findings, Old/New Caveats and Future Perspectives.The Role of PPAR Gamma in Systemic Sclerosis.The emerging role of hepatocyte growth factor in renal diseases.MiRNA-200b represses transforming growth factor-β1-induced EMT and fibronectin expression in kidney proximal tubular cells.Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts.PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells.PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density.
P2860
Q28581020-CAEB2955-2490-4874-8DD7-3FCB21F4C10EQ33560989-FEF988AD-F9FF-483D-968E-4F02CADD4B7DQ33669422-3BF538EB-F4B5-44BE-A849-692B82520938Q33800620-1D861497-4883-40CA-966E-3F7B9F83A399Q34068447-370188FD-4BF4-4F23-8D0A-2EA5CC810E7AQ34103484-9ACFA861-0BAD-4D7F-A9F8-87CB3386A5E5Q34542329-AD97BAA5-F5B4-470E-8EBE-0018574BB81BQ34627478-F175BCF7-9A36-47EA-B65C-4A93140012FEQ34736911-BE06EB6C-E297-48E6-B91A-8E310588FC6AQ35234337-FFAB5EB9-26C2-4E90-B542-802E261DFFB7Q35503543-D4619884-DC78-4698-85BD-26A285A5A9F6Q35925362-53653DB2-B043-4597-9F49-64D0547B633EQ35954579-FED84D62-9946-4D83-BA1F-E5515DBD2088Q36093802-F39AB7F9-90FF-49CC-A876-45F835CE02E3Q36151652-7904F241-A28E-407D-8B66-5409FF02425DQ36605155-6A83A291-4E30-45CA-906E-B82CD0D9FDA4Q36741213-870B66CA-60F4-4640-9EC9-26173DB2EE35Q36743890-55F587AE-5F73-4B28-A066-80C95493DAB7Q36824736-477D4CAA-D36D-4DEF-8B0D-3214362AB00DQ37071874-499B2047-7621-4F86-8FE0-2A025C9ED0FFQ37072216-A3917BB1-AC87-4A97-A7AF-EB83889164A4Q37129649-74AD7A5A-BCBE-4339-87F8-FB79A1B39D2EQ37186311-68FB8E63-C87A-4C88-A56F-5C1880807D3AQ37326935-552989F1-8B73-43CA-B914-E34FADA410E6Q37330584-C2ACC821-3303-4A15-8016-C8AACC76624BQ37410310-CFA20E34-496C-4AC1-A924-0A2834A0CC42Q37686310-C81DF939-911B-40EB-BFAF-B463D474BC08Q37765370-E6C15848-01C0-47F0-8D28-D96297142CE7Q37777055-AC24D4C3-CC7F-4205-B73E-26547749D8A9Q37861626-5C22B733-8217-45E8-8EE6-9DC279E42C3BQ38300981-1DE86970-C268-4C48-9A5E-17788116D835Q38355897-3ADD7F43-39CE-489F-8E33-E5C52764C7EAQ38395222-EE76CE34-0457-459D-A1B4-33850B3C94A0Q38524619-4BDA1F51-BAC1-4F47-AF55-03824A9F4208Q38605788-9E294C99-F10B-4222-B819-C46AE968193EQ39194879-9333B1A6-18F5-430A-A5E6-AE6BE019FE13Q39771067-16EF419B-EBEA-4A65-B6FD-8716F6D29193Q40225700-69B7C882-5D11-458C-AAF7-28ADB4D886C4Q41879222-71385C9D-A18A-4DD3-8762-78FEE41F2F4DQ42801338-6F8FEFF8-955F-4BEF-B786-BDAA6F191A26
P2860
hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
hepatocyte growth factor is a ...... vated receptor-gamma agonists.
@ast
hepatocyte growth factor is a ...... vated receptor-gamma agonists.
@en
type
label
hepatocyte growth factor is a ...... vated receptor-gamma agonists.
@ast
hepatocyte growth factor is a ...... vated receptor-gamma agonists.
@en
prefLabel
hepatocyte growth factor is a ...... vated receptor-gamma agonists.
@ast
hepatocyte growth factor is a ...... vated receptor-gamma agonists.
@en
P2093
P2860
P356
P1476
hepatocyte growth factor is a ...... vated receptor-gamma agonists.
@en
P2093
Bradley C Spataro
Chunsun Dai
Xiaoyan Wen
Yingjian Li
Youhua Liu
P2860
P356
10.1681/ASN.2005030257
P577
2005-11-16T00:00:00Z